NuMedii

Cyclica will soon begin testing a commercial version of its services software this summer ahead of a full launch planned for next year.

Using funds from the California precision medicine initiative, the group will use its bioinformatics expertise to match patients to treatments in pediatric clinical trials.

The initiative aims to integrate clinical, genomic, environmental, and other data from patients to help determine disease mechanisms and develop precise therapies.

In April, Butte became director of UCSF's Institute for Computational Health Sciences and executive director of clinical informatics for UC Health Sciences and Services. 

Thomson Reuters and NuMedii this week announced a partnership that will pair NuMedii's underlying informatics technology with curated drug and disease information and systems biology expertise from Thomson Reuters for use in identifying new applications for existing drugs.

Atul Butte, an associate professor in Stanford University's School of Medicine, was recently named as one of 13 Open Science Champions of Change by the White House's Office of Science and Technology Policy for his efforts to use and support open data in biomedical research.

NEW YORK (GenomeWeb News) – NuMedii announced today that it has raised $3.5 million in a Series A funding round led by Claremont Creek Ventures and Lightspeed Venture Partners with participation from Life Science Angels and others.

NuMedii said this week that it will use its predictive platform to identify potential therapeutic candidates for gastrointestinal disorders and cystic fibrosis for Aptalis Pharma.

By Uduak Grace Thomas
NuMedii, a Stanford University spinoff, hopes to make its bread and butter by partnering with traditional and specialty pharmaceutical companies to identify new indications for existing medicines.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.